Table 2.
Baseline characteristics for continuation outcomes on PP3M and PPLAI.
| Characteristic | Total | PP3M continuers | PP3M discontinuers a | PPLAI continuers | PPLAI discontinuers a | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 186 | n = 110 | n = 76 | n = 129 | n = 57 | ||||||
| Age on initiation of PP3M (years) | ||||||||||
| Mean, SD | 45, 13.2 | 46, 11.7 | 44, 15.1 | 47, 12.3 | 42, 14.4 | |||||
| Min, max | 20, 77 | 22, 74 | 20, 77 | 22, 77 | 20, 74 | |||||
| Prior duration of PP1M (months) | ||||||||||
| Mean, SD | 34, 24.5 | 35, 25.1 | 34, 23.7 | 37, 24.9 | 28, 22.5 | |||||
| Min, max | 3, 89 | 3, 89 | 3, 81 | 3, 89 | 3, 81 | |||||
Abbreviations: PPLAI, paliperidone long-acting injection; PP1M, one monthly paliperidone; PP3M, Paliperidone 3-monthly; SD, standard deviation.
a
Discontinuers includes those who stopped due to death or being lost to follow-up.
b
Asian refers to Indian—subcontinent as per NHS ethnicity classification.